Unresectable Malignant Solid Neoplasm clinical trials at UC Health
1 research study open to eligible people
open to eligible people ages 18 years and up
This pilot phase I trial studies the side effects of atezolizumab in treating patients with cancer following adoptive cell transfer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.